Systemic siRNA delivery via peptide-tagged polymeric nanoparticles, targeting PLK1 gene in a mouse xenograft model of colorectal cancer

International Journal of Biomaterials

Volumn 2013, Issue , 2013, Pages

  Malhotra, Meenakshi ^a   Tomaro Duchesneau, Catherine ^a   Saha, Shyamali ^a,b   Prakash, Satya ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELL TARGETING PEPTIDE 15; CHITOSAN; MACROGOL; NANOPARTICLE; PEPTIDE; POLO LIKE KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HISTOPATHOLOGY; IN VIVO STUDY; LIVER TOXICITY; MOUSE; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 84885651607     PISSN: 16878787     EISSN: 16878795     Source Type: Journal    
DOI: 10.1155/2013/252531     Document Type: Article

References (58)

1. Anand P., Kunnumakkara A. B., Sundaram C., Harikumar K. B., Tharakan S. T., Lai O. S., Sung B., Aggarwal B. B., Cancer is a preventable disease that requires major lifestyle changes. Pharmaceutical Research 2008 25 9 2097 2116 2-s2.0-53049089942 10.1007/s11095-008-9661-9
2. Knudson A. G., Two genetic hits (more or less) to cancer. Nature Reviews Cancer 2001 1 2 157 162 2-s2.0-0035522894 (Pubitemid 33741891)
3. Sargent D., Sobrero A., Grothey A., O'Connell M. J., Buyse M., Andre T., Zheng Y., Green E., Labianca R., O'Callaghan C., Seitz J. F., Francini G., Haller D., Yothers G., Goldberg R., De Gramont A., Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. Journal of Clinical Oncology 2009 27 6 872 877 2-s2.0-60849123935 10.1200/JCO.2008.19.5362
4. Mosolits S., Nilsson B., Mellstedt H., Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Review of Vaccines 2005 4 3 329 350 2-s2.0-22144433725 10.1586/14760584.4.3.329 (Pubitemid 40978696)
5. Wang G., Kelley R. K., GAPPNet. KRAS mutational analysis for colorectal cancer application: pharmacogenomic. PLOS Currents 2010 2 RRN1175 10.1371/currents.RRN1175
6. Eckerdt F., Yuan J., Strebhardt K., Polo-like kinases and oncogenesis. Oncogene 2005 24 2 267 276 2-s2.0-13244269808 10.1038/sj.onc.1208273 (Pubitemid 40188607)
7. Takai N., Hamanaka R., Yoshimatsu J., Miyakawa I., Polo-like kinases (Plks) and cancer. Oncogene 2005 24 2 287 291 2-s2.0-13244271313 10.1038/sj.onc.1208272 (Pubitemid 40188609)
8. Ando K., Ozaki T., Yamamoto H., Furuya K., Hosoda M., Hayashi S., Fukuzawa M., Nakagawara A., Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. Journal of Biological Chemistry 2004 279 24 25549 25561 2-s2.0-2942623616 10.1074/jbc.M314182200 (Pubitemid 38756815)
9. Spänkuch-Schmitt B., Bereiter-Hahn J., Kaufmann M., Strebhardt K., Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. Journal of the National Cancer Institute 2002 94 24 1863 1877 2-s2.0-0037132736 (Pubitemid 36104631)
10. Liu X., Erikson R. L., Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003 100 10 5789 5794 2-s2.0-0038624074 10.1073/pnas.1031523100 (Pubitemid 36576886)
11. Liu X., Lei M., Erikson R. L., Normal cells, but not cancer cells, survive severe Plk1 depletion. Molecular and Cellular Biology 2006 26 6 2093 2108 2-s2.0-33644767315 10.1128/MCB.26.6.2093-2108.2006 (Pubitemid 43346913)
12. Guan R., Tapang P., Leverson J. D., Albert D., Giranda V. L., Luo Y., Small interfering RNA-mediated polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Research 2005 65 7 2698 2704 2-s2.0-16844369144 10.1158/0008-5472.CAN-04-2131 (Pubitemid 40490070)
13. Lane H. A., Nigg E. A., Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. Journal of Cell Biology 1996 135 6 1701 1713 2-s2.0-0030462914 10.1083/jcb.135.6.1701 (Pubitemid 27036434)
14. Cogswell J. P., Brown C. E., Bisi J. E., Neill S. D., Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth and Differentiation 2000 11 12 615 623 2-s2.0-0034520085 (Pubitemid 32042984)
15. Nahta R., Esteva F. J., Herceptin: mechanisms of action and resistance. Cancer Letters 2006 232 2 123 138 2-s2.0-31644439702 10.1016/j.canlet.2005.01. 041 (Pubitemid 43170962)
16. Valabrega G., Montemurro F., Aglietta M., Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of Oncology 2007 18 6 977 984 2-s2.0-34447306848 10.1093/annonc/mdl475 (Pubitemid 47050487)
17. Chopra P., Sethi G., Dastidar S. G., Ray A., Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opinion on Investigational Drugs 2010 19 1 27 43 2-s2.0-72049090437 10.1517/ 13543780903483191
18. Tekmira Pharmaceuticals Corporation, Dose Escalation Study to Determine Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301. Identifier: NCT01262235, http://www.clinicaltrials.gov/
19. Chen S. H., Zhaori G., Potential clinical applications of siRNA technique: benefits and limitations. European Journal of Clinical Investigation 2011 41 2 221 232 2-s2.0-78651314500 10.1111/j.1365-2362.2010.02400.x
20. Kiefer K., Clement J., Garidel P., Peschka-Süss R., Transfection efficiency and cytotoxicity of nonviral gene transfer reagents in human smooth muscle and endothelial cells. Pharmaceutical Research 2004 21 6 1009 1017 2-s2.0-3042845524 10.1023/B:PHAM.0000029291.62615.ec (Pubitemid 38870152)
21. Yoo J. W., Hong S. W., Kim S., Lee D., Inflammatory cytokine induction by siRNAs is cell type- and transfection reagent-specific. Biochemical and Biophysical Research Communications 2006 347 4 1053 1058 2-s2.0-33746368839 10.1016/j.bbrc.2006.07.001 (Pubitemid 44118221)
22. Mirus-The Transfection Experts. 2011
23. Polyplus-The Delivery Experts. 2011
24. Turbofect In-Vivo Transfection Reagent-Fermentas. 2011
25. Sigma Aldrich, N-TER Nanoparticle siRNA Transfection System. 2011
26. McNeil S. E., Nanotechnology for the biologist. Journal of Leukocyte Biology 2005 78 3 585 594 2-s2.0-24744447202 10.1189/jlb.0205074 (Pubitemid 41292080)
27. Aigner A., Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. Journal of Biomedicine and Biotechnology 2006 2006 15 2-s2.0-33746581992 10.1155/JBB/2006/71659 71659 (Pubitemid 44147737)
28. Zhang Y., Chen J., Zhang Y., Hu Z., Hu D., Pan Y., Ou S., Liu G., Yin X., Zhao J., Ren L., Wang J., Panning and identification of a colon tumor binding peptide from a phage display peptide library. Journal of Biomolecular Screening 2007 12 3 429 435 2-s2.0-34047111229 10.1177/1087057106299164 (Pubitemid 46514673)
29. Malhotra M., Tomaro-Duchesneau C., Prakash S., Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 2013 34 4 1270 1280 10.1016/j.biomaterials.2012.10.013
30. Malhotra M., Kulamarva A., Sebak S., Paul A., Bhathena J., Mirzaei M., Prakash S., Ultrafine chitosan nanoparticles as an efficient nucleic acid delivery system targeting neuronal cells ultrafine nanoparticles siRNA delivery system. Drug Development and Industrial Pharmacy 2009 35 6 719 726 2-s2.0-70350589264 10.1080/03639040802526789
31. Prakash S., Malhotra M., Shao W., Tomaro-Duchesneau C., Abbasi S., Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Advanced Drug Delivery Reviews 2011 63 14-15 1340 1351 2-s2.0-81355138643 10.1016/j.addr.2011.06.013
32. Haley B., Frenkel E., Nanoparticles for drug delivery in cancer treatment. Urologic Oncology 2008 26 1 57 64 2-s2.0-37649010361 10.1016/j.urolonc.2007.03.015
33. Cho Y. W., Kim J., Park K., Polycation gene delivery systems: escape from endosomes to cytosol. Journal of Pharmacy and Pharmacology 2003 55 6 721 734 2-s2.0-0038205763 10.1211/002235703765951311 (Pubitemid 36752715)
34. Liu X., Howard K. A., Dong M., Andersen M. Ø., Rahbek U. L., Johnsen M. G., Hansen O. C., Besenbacher F., Kjems J., The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007 28 6 1280 1288 2-s2.0-33751419974 10.1016/j.biomaterials.2006.11.004 (Pubitemid 44816373)
35. Bae Y. H., Park K., Targeted drug delivery to tumors: myths, reality and possibility. Journal of Controlled Release 2011 153 3 198 205 2-s2.0-79960925147 10.1016/j.jconrel.2011.06.001
36. Wang A. Z., Langer R., Farokhzad O. C., Nanoparticle delivery of cancer drugs. Annual Review of Medicine 2012 63 185 198 2-s2.0-84855961163 10.1146/annurev-med-040210-162544
37. Huang L., Guo S., Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy. Journal of Nanomaterials 2011 2011 12 2-s2.0-80053535575 10.1155/2011/742895 742895
38. Tobin L. A., Xie Y., Tsokos M., Chung S. I., Merz A. A., Arnold M. A., Li G., Malech H. L., Kwong K. F., Pegylated siRNA-loaded calcium phosphate nanoparticle-driven amplification of cancer cell internalization in-vivo. Biomaterials 2013 34 12 2980 2990 10.1016/j.biomaterials.2013.01.046
39. Choi K. Y., Min K. H., Yoon H. Y., Kim K., Park J. H., Kwon I. C., Choi K., Jeong S. Y., PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011 32 7 1880 1889 2-s2.0-78650987029 10.1016/j.biomaterials.2010.11.010
40. Gref R., Lück M., Quellec P., Marchand M., Dellacherie E., Harnisch S., Blunk T., Müller R. H., 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids and Surfaces B 2000 18 3-4 301 313 2-s2.0-0343191443 10.1016/S0927-7765(99)00156-3 (Pubitemid 30479870)
41. Hak S., Helgesen E., Hektoen H. H., The effect of nanoparticle polyethylene glycol surface density on ligand-directed tumor targeting studied in-vivo by dual modality imaging. ACS Nano 2012 6 6 5648 5658 10.1021/nn301630n
42. Malhotra M., Tomaro-Duchesneau C., Saha S., Prakash S., Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. International Journal of Nanomedicine 2013 8 2041 2052
43. Ishida T., Kiwada H., Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. International Journal of Pharmaceutics 2008 354 1-2 56 62 2-s2.0-40849138014 10.1016/j.ijpharm.2007.11. 005
44. Ishihara T., Maeda T., Sakamoto H., Takasaki N., Shigyo M., Ishida T., Kiwada H., Mizushima Y., Mizushima T., Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules 2010 11 10 2700 2706 2-s2.0-77957870398 10.1021/bm100754e
45. Sherman M. R., Williams L. D., Sobczyk M. A., Michaels S. J., Saifer M. G. P., Role of the methoxy group in immune responses to mpeg-protein conjugates. Bioconjugate Chemistry 2012 23 3 485 499 2-s2.0-84858710067 10.1021/bc200551b
46. Spänkuch B., Steinhauser I., Wartlick H., Kurunci-Csacsko E., Strebhardt K. I., Langer K., Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles. Neoplasia 2008 10 3 223 234 2-s2.0-40149097015 10.1593/neo.07916 (Pubitemid 351328583)
47. Steinhauser I., Langer K., Strebhardt K., Spänkuch B., Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression. Journal of Drug Targeting 2009 17 8 627 637 2-s2.0-70350452387 10.1080/10611860903118823
48. Dharmapuri S., Peruzzi D., Marra E., Palombo F., Bett A. J., Bartz S. R., Yong M., Ciliberto G., La Monica N., Buser C. A., Toniatti C., Aurisicchio L., Intratumor RNA interference of cell cycle genes slows down tumor progression. Gene Therapy 2011 18 7 727 733 2-s2.0-79960122358 10.1038/gt.2011.27
49. Schmidt M. M., Wittrup K. D., A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Molecular Cancer Therapeutics 2009 8 10 2861 2871 2-s2.0-70350234894 10.1158/1535-7163.MCT-09- 0195
50. Choi C. H. J., Alabi C. A., Webster P., Davis M. E., Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proceedings of the National Academy of Sciences of the United States of America 2010 107 3 1235 1240 2-s2.0-75749088450 10.1073/pnas.0914140107
51. Sanvicens N., Marco M. P., Multifunctional nanoparticles-properties and prospects for their use in human medicine. Trends in Biotechnology 2008 26 8 425 433 2-s2.0-47049099053 10.1016/j.tibtech.2008.04.005
52. Mishra S., Webster P., Davis M., PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. European Journal of Cell Biology 2004 83 3 97 111 2-s2.0-2942632966 10.1078/0171-9335-00363 (Pubitemid 38765217)
53. Tech note: In-vivo RNAi: Biodistribution, Delivery, and Applications. Thermoscientificbio
54. Li X., Chen Y., Wang M., Ma Y., Xia W., Gu H., A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013 34 4 1391 1401 10.1016/j.biomaterials.2012.10.072
55. Kim W. J., Yockman J. W., Jeong J. H., Christensen L. V., Lee M., Kim Y., Kim S. W., Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice. Journal of Controlled Release 2006 114 3 381 388 2-s2.0-33748160118 10.1016/j.jconrel.2006.05.029 (Pubitemid 44310812)
56. Czauderna F., Fechtner M., Dames S., Aygün H., Klippel A., Pronk G. J., Giese K., Kaufmann J., Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Research 2003 31 11 2705 2716 2-s2.0-0038606999 10.1093/nar/gkg393 (Pubitemid 37442115)
57. Robbins M., Judge A., Liang L., McClintock K., Yaworski E., MacLachlan I., 2′-O-methyl-modified RNAs act as TLR7 antagonists. Molecular Therapy 2007 15 9 1663 1669 2-s2.0-34548108038 10.1038/sj.mt.6300240 (Pubitemid 47289010)
58. Malhotra M., Nambiar S., Rengaswamy V., Prakash S., Small interfering ribonucleic acid design strategies for effective targeting and gene silencing. Expert Opinion on Drug Discovery 2011 6 3 269 289 2-s2.0-79952238110 10.1517/17460441.2011.555394